ADVICENNE

ADVICENNE releases a comprehensive regulatory update, detailing voting shares and capital structure to boost transparency and investor confidence in the pharma sector.

Advicenne’s unlimited UK renewal of Sibnayal for rare kidney disease shows its growing leadership in pediatric nephrology and boosts market reach.